|
1
|
Kligerman S and White C: Epidemiology of
lung cancer in women: Risk factors, survival, and screening. AJR Am
J Roentgenol. 196:287–295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yang JC, Kang JH, Mok T, Ahn MJ,
Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S,
et al: First-line pemetrexed plus cisplatin followed by gefitinib
maintenance therapy versus gefitinib monotherapy in East Asian
patients with locally advanced or metastatic non-squamous non-small
cell lung cancer: A randomised, phase 3 trial. Eur J Cancer.
50:2219–2230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brown T, Boland A, Bagust A, Oyee J,
Hockenhull J, Dundar Y, Dickson R, Ramani VS and Proudlove C:
Gefitinib for the first-line treatment of locally advanced or
metastatic non-small cell lung cancer. Health Technol Assess. 14
(Suppl):71–99. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mendoza L: Targeted therapies in the
treatment of advanced non-small-cell lung cancer: Update. Klin
Onkol. 22:131–138. 2009.PubMed/NCBI
|
|
5
|
Avery EJ, Kessinger A and Ganti AK:
Therapeutic options for elderly patients with advanced non-small
cell lung cancer. Cancer Treat Rev. 35:340–344. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahn HK, Choi YL, Han JH, Ahn YC, Kim K,
Kim J, Shim YM, Um SW, Kim H, Kwon OJ, et al: Epidermal growth
factor receptor mutation and treatment outcome of mediastinoscopic
N2 positive non-small cell lung cancer patients treated with
neoadjuvant chemoradiotherapy followed by surgery. Lung Cancer.
79:300–306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanaka K, Hida T, Oya Y, Oguri T, Yoshida
T, Shimizu J, Horio Y, Hata A, Kaji R, Fujita S, et al: EGFR
mutation impact on definitive concurrent chemoradiation therapy for
inoperable stage III adenocarcinoma. J Thorac Oncol. 10:1720–1725.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dahabreh IJ, Linardou H, Kosmidis P,
Bafaloukos D and Murray S: EGFR gene copy number as a predictive
biomarker for patients receiving tyrosine kinase inhibitor
treatment: A systematic review and meta-analysis in non-small-cell
lung cancer. Ann Oncol. 22:545–552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fukuoka M, Wu YL, Thongprasert S,
Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu
DT, Saijo N, et al: Biomarker analyses and final overall survival
results from a phase III, randomized, open-label, first-line study
of gefitinib versus carboplatin/paclitaxel in clinically selected
patients with advanced non-small-cell lung cancer in Asia (IPASS).
J Clin Oncol. 29:2866–2874. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Murphy M and Stordal B: Erlotinib or
gefitinib for the treatment of relapsed platinum pretreated
non-small cell lung cancer and ovarian cancer: A systematic review.
Drug Resist Updat. 14:177–190. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pirker R: What is the best strategy for
targeting EGF receptors in non-small-cell lung cancer. Future
Oncol. 11:153–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cheng Q, Yi B, Wang A and Jiang X:
Exploring and exploiting the fundamental role of microRNAs in tumor
pathogenesis. Oncol Targets Ther. 6:1675–1684. 2013.
|
|
13
|
Xia H and Hui KM: MicroRNAs involved in
regulating epithelial-mesenchymal transition and cancer stem cells
as molecular targets for cancer therapeutics. Cancer Gene Ther.
19:723–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weiss GJ, Bemis LT, Nakajima E, Sugita M,
Birks DK, Robinson WA, Varella-Garcia M, Bunn PA Jr, Haney J,
Helfrich BA, et al: EGFR regulation by microRNA in lung cancer:
Correlation with clinical response and survival to gefitinib and
EGFR expression in cell lines. Ann Oncol. 19:1053–1059. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chheang S and Brown K: Lung cancer
staging: Clinical and radiologic perspectives. 30:99–113.
2013.PubMed/NCBI
|
|
16
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, Wen Q, Xu L, Xie G, Li J, Luo J,
Chu S, Shi L, Huang D, Li J and Fan S: Activation of Akt/mTOR
pathway is associated with poor prognosis of nasopharyngeal
carcinoma. PLoS One. 9:e1060982014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ling LI and Song LH: The role of MicroRNA
in lung cancer. J Clin Oncol. 36:1377–1380. 2009.(In Chinese).
|
|
19
|
Zhao N, Zhang XC, Yan HH, Yang JJ and Wu
YL: Efficacy of epidermal growth factor receptor inhibitors versus
chemotherapy as second-line treatment in advanced non-small-cell
lung cancer with wild-type EGFR: A meta-analysis of randomized
controlled clinical trials. Lung Cancer. 85:66–73. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang S, Su X, Bai H, Zhao J, Duan J, An T,
Zhuo M, Wang Z, Wu M, Li Z, et al: Identification of plasma
microRNA profiles for primary resistance to EGFR-TKIs in advanced
non-small cell lung cancer (NSCLC) patients with EGFR activating
mutation. J Hematol Oncol. 8:1272015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Duan X and Shi J: Advance in microRNAs and
EGFR-TKIs secondary resistance research in non-small cell lung
cancer. Zhongguo Fei Ai Za Zhi. 17:860–864. 2014.(In Chinese).
PubMed/NCBI
|
|
22
|
Aichler M, Motschmann M, Jütting U, Luber
B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR and
Walch A: Epidermal growth factor receptor (EGFR) is an independent
adverse prognostic factor in esophageal adenocarcinoma patients
treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget.
5:6620–6632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ludovini V, Bellezza G, Pistola L,
Bianconi F, Di Carlo L, Sidoni A, Semeraro A, Del Sordo R,
Tofanetti FR, Mameli MG, et al: High coexpression of both
insulin-like growth factor receptor-1 (IGFR-1) and epidermal growth
factor receptor (EGFR) is associated with shorter disease-free
survival in resected non-small-cell lung cancer patients. Ann
Oncol. 20:842–849. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Du L, Schageman JJ, Subauste MC, Saber B,
Hammond SM, Prudkin L, Wistuba II, Ji L, Roth JA, Minna JD and
Pertsemlidis A: miR-93, miR-98, and miR-197 regulate expression of
tumor suppressor gene FUS1. Mol Cancer Res. 7:1234–1243. 2009.
View Article : Google Scholar : PubMed/NCBI
|
